FDA compounder NDC directory
Browse every current FDA compounder source row, including records that do not contain a usable NDC.
Compounder NDC directory#
Every current compounder source row is browsable, including records whose FDA source did not provide a usable product, package, or lookup NDC. Browse the unified current auxiliary catalog. · Browse the complete captured source and snapshot history.
| Establishment | FEI | Product NDC | Package NDC | Brand | Nonproprietary name | Active ingredients | Period | Normalization | Source date |
|---|---|---|---|---|---|---|---|---|---|
| Hybrid Pharma | 079665742 | 26436-5177 | 26436-5177-2 | Alprostadil; Papaverine Hydrobromide; Phentolamine Mesylate | 50 ug/1 mL; 30 mg/1 mL; 2 mg/1 mL | 2025-1 | valid | 2026-10-13 | |
| Hybrid Pharma | 26436-5177 | 26436-5177-2 | Trimix 50/30/2 | Trimix 50/30/2 | 50 ug/1 mL; 30 mg/1 mL; 2 mg/1 mL | 2025-1 | valid | 2026-09-18 | |
| Hybrid Pharma | 079665742 | 26436-5177 | 26436-5177-2 | Alprostadil; Papaverine Hydrobromide; Phentolamine Mesylate | 50 ug/1 mL; 30 mg/1 mL; 2 mg/1 mL | 2024-1 | valid | 2026-10-13 | |
| Hybrid Pharma | 079665742 | 26436-5177 | 26436-5177-2 | Alprostadil; Papaverine Hydrobromide; Phentolamine Mesylate | 50 ug/1 mL; 30 mg/1 mL; 2 mg/1 mL | 2023-2 | valid | 2026-10-13 | |
| Hybrid Pharma | 079665742 | 26436-5177 | 26436-5177-2 | Papaverine Hydrobromide; Phentolamine Mesylate; Alprostadil | 30 mg/1 mL; 2 mg/1 mL; 50 ug/1 mL | 2021-2 | valid | 2026-10-13 |